Phase 2 N=83 S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer
Colorectal Cancer
Primary: Pathologic Complete Response Rate — 25 percentage of participants — p=0.18
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=237 A Study of the Efficacy and Safety of Synvisc® in Chinese Subjects With Symptomatic Osteoarthritis of the Knee(s)
Osteoarthritis
Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) A1 Subscore (Walking Pain) at Week 26 — -33.0 mm — p=<0.0001
Phase 3 N=175 TRARO (Traumeel® S in Rotator Cuff Syndrome)-Study
Rotator Cuff Syndrome · Shoulder Bursitis
Primary: Change From Baseline in Abduction Rotation Pain VAS at Visit 5 (Day 22) (Traumeel® S Injections Versus Fortecortin) for Active External Rotation — -18.7; -27.2 units on…
Phase 2 N=32 Efficacy and Safety of Bisacodyl and Lactulose as a Preparation for Colonoscopy
Colonoscopy Preparation
Primary: Efficacy of Bisacodyl and Lactulose as a Preparation for Colonoscopy. — 5.7; 7.4; 7.8 units on a scale
N/A N=63 Intraoperative Ocular Pressure in Lumbar Spine Fusion Patients
Raised Ocular Pressure
Primary: Change in Intraoperative Ocular Pressure in Lumbar Spine Fusion Patients Head Raised 10 Degrees or Kept in Neutral Position — 9.26; 13.79 mm Hg
Phase 4 N=74 MRI and Neurodevelopment in Preterm Infants Following Administration of High-Dose Caffeine
Apnea of Prematurity · Intraventricular Hemorrhage · Brain Injury
Primary: White Matter Microstructural Maturation — 1.43; 1.42 apparent diffusion coefficient
N/A N=66 Helping Families Help Veterans With PTSD and Alcohol Abuse: An RCT of VA-CRAFT
PTSD · Alcohol Abuse
Primary: Veteran Engagement in VA Mental Health Services — 4; 4 participants — p=0.927
Phase 2 N=24 A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris
Psoriasis Vulgaris
Primary: Absolute Change in Total Clinical Score (TCS) of Clinical Signs (Sum of Erythema, Scaling and Infiltration) at End of Treatment Compared to Baseline — -6.00; -4.96…
Phase 3 N=627 A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Progression Free Survival — 154; 168 days — p=0.00584
Phase 2 N=32 Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release
Breast Cancer · Non-Hodgkin's Lymphoma
Primary: TNF-alpha Levels in Patients Receiving Doxorubicin Containing Chemotherapy — 3.55; 3.68; 2.95; 3.18 log(pg/ml) — p=0.014
N/A N=160 An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years
Breast Cancer
Primary: Tumor Hormone Receptor Status of Participants Without Progression — 57.6; 42.4 Percentage of participants
N/A N=633 Connect to Quit for Smoking
Smoking · Smoking Cessation
Primary: Effectiveness of CTQ vs UC — 7.5; 6.1 percentage of participants per arm
Phase 2 N=29 Beating the Blues for Your Heart
Depression · Depressive Symptoms · Cardiovascular Disease (CVD)
Primary: Post-Treatment Brachial Flow-Mediated Dilation (FMD) Adjusted for Pre-Treatment FMD — 4.18; 2.47 % change in brachial diameter — p=.21
Phase 4 N=60 Dexmedetomidine and Propofol in Children With History of Obstructive Sleep Apnea
Sleep Apnea, Obstructive
Primary: Cross Sectional Area of the Pharyngeal Airway — 239.9; 178.5; 201.6; 235.4 mm^2
N/A N=7 Testing Beliefs About Uncertainty in the Treatment of Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Clinician's Severity Rating (CSR) Scale of Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV) — 5.5; 3.14; 2.43 units on a scale